

IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

Corrigenda – Corporate Governance Reports 2022 and 2023

The Board of Directors of iX Biopharma Ltd (the “**Company**”) refers to the Corporate Governance Reports set out in the Company’s 2022 Annual Report and 2023 Annual Report published on 22 September 2022 and 26 September 2023, respectively.

The Company wishes to correct the errors in the remuneration band of Mr Eddy Lee Yip Hang disclosed under Disclosure of Remuneration (Provisions 8.1 & 8.3) in the Corporate Governance Reports in the manner set out below:

1. On page 33 of the 2022 Annual Report, replace “\$750,001 to \$1,000,000” with “\$1,250,001 to \$1,500,000”; and
2. On page 34 of the 2023 Annual Report, replace “\$1,250,001 to \$1,500,000” with “\$1,000,001 to \$1,250,000”.

The above corrections do not affect the financial statements for the financial year ended 30 June 2022 and 30 June 2023.

By Order of the Board

Gwendoline Lee Soo Fern
Company Secretary

4 October 2023

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.